Combined treatment with APCC (FEIBA ®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A - a two-centre experience

Haemophilia

Volumn 18, Issue 4, 2012, Pages 544-549

  Holmstrom M ^a   Tran, H T T ^b   Holme, P A ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

APCC; Haemophilia; Inhibitors; Tranexamic acid

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; TRANEXAMIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEMARTHROSIS; HEMOPHILIA A; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; MUSCLE BLEEDING; NORWAY; ORAL BLEEDING; PRIORITY JOURNAL; SWEDEN; THROMBIN TIME; THROMBOELASTOGRAPHY; TREATMENT OUTCOME; VEIN THROMBOSIS;

ADULT; AGED; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; COAGULANTS; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; THROMBELASTOGRAPHY; THROMBIN; TRANEXAMIC ACID; YOUNG ADULT;

EID: 84863222250     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02748.x     Document Type: Article

References (33)

1. Carr ME Jr, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coag Fibrinolysis 1995; 6: 567-73.
2. He S, Blomback M, Ekman GJ, Hedner U. The role of recombinant factor FVIIa (rFVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 1: 1215-9.
3. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose of rFVIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131: 645-55.
4. Johansson T, Pettersson LG, Lisander B. Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, doubleblind study in 100 patients. Acta Orthop 2005; 131: 645-55.
5. Jansen AJ, Andreica S, Claeys M, D′Haese J, Camu F, Jochmans K. Use of tranexamic acid for an effective blood conservation strategy after total knee arthropalsty. Br J Anaesth 1999; 83: 596-601.
6. Veien M, Sorensen JV, Madsen F, Juelsgaard P. Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized controlled study Acta. Anaesthesiol Scand 2002; 46: 1206-11.
7. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999; 57: 1005-32.
8. Philipp CS. Antifibrinolytics in women with menorrhagia. Thromb Res 2011; 127S3: S113-5.
9. CRASH-2-trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaisvilli T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi O, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects on death, vascular occlusive events in trauma patients with significant haemorrhage: a randomised, placebo-controlled trialLancet 2010; 376: 23-32.
10. Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001;1:CD001886.
11. Hermans C, Altisent C, Batorova A et al. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European Survey and recommendations. Haemophilia 2009; 15: 639-58.
12. Schulman S, Loogna J, Wallensten R. Minimizing factor requirements for surgery without increased risk. Haemophilia 2004; 10(Suppl. 4): 35-40.
13. Lee AP, Boyle CA, Savidge GF, Fiske J. Effectiveness in controlling hemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. Br Dent J 2005; 198: 33-8.
14. Cathrine R, Foley JH, Ingerslev J, Sørensen B. Factor XIII combined with recombinant factor VIIa: A new means of treating severe haemophilia A. J Thorrmb Haemost 2011; 9: 510-6.
15. Hvas A-M, Sørensen HT, Norengaard L, Christiansen K, Ingerslev J, Sørensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibirnolysis in severe hemophilia. A J Thrormb Haemost 2007; 5: 2408-14.
16. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A. A systematic review. Haemophilia 2003; 9: 418-35.
17. UK Haemophilia Centre Doctors' Organization. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
18. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor VIII Bypassing Activity. Thromb Haemost 1997; 77: 1113-9.
19. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
20. HTRS Registry Investigators, Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
21. Astermark J, Donfield SM, DiMichele DM et al. For the FENOC Study GroupArandomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood, 2007; 109:2
22. Dai L, Bevan D, Rangarajan S, Sørensen B, Mitchell M. Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma. Haemophilia 2011; 17: e944-8.
23. Rodriguez-Merchan EC, Rocino A, Ewenstein B et al. Consensus perspective on surgery in haemophilia patients with inhibitors summary statement. Haemophilia 2004; 10: 50-2.
24. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost 1998; 79: 872-5.
25. Ghosh K, Shetty JF, Mohanty D. Role of epsilon amino caproic acid in the management of haemophilic patient with inhibitors. Haemophilia 2004; 10: 58-62.
26. Rangarajan S, Yee TT, Wilde J. Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors. Haemophilia 2011; 17: 28-34.
27. Tjonnfjord GE, Brinch L, Gedde-Dahl T, Brosstad F. Activated prothombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004; 10: 174-8.
28. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2008; 14: 39-43.
29. Preston FE, Dinsdale RC, Sutcliffe DJ, Bardhan G, Wyld PJ, Hamlyn JF. Factor VIII inhibitor by-passing activity (FEIBA) in the management of patients with factor VIII inhibitors. Thromb Res 1977; 11: 643-51.
30. Agrestini F, Solinas S, Marinelli M, Avvisati G, Badia D, Mazzucconi MG. Activated prothrombin complex concentrates in dental extractions and oral and minor surgery in hemophiliacs with high-titer inhibitor. In: Mariani G, Russo MA, Mandelli F, eds. Activated Prothrombin Complex Concentrates: Managing Hemophilia with Factor VIII inhibitor, NewYork: Praeger Publishers, 1982: 168-75.
31. Stenbjerg S, Tauris P, Skottun T, Jørgensen J. Total dental extraction in a patient with FVIII inhibitor. Thromb Res 1980; 18: 889-93.
32. Yesim D, Linhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoringof bypassing therapy in haemophilia patients with inhibitors undergoing selective surgery. Blood 2010; 116: 5734-7.
33. Dehmel H, Werwitzke S, Trummer A, Ganser A, Tiede A. Thromboelastographic monitoring of recombinant factor FVIIa in acquired haemophilia. Haemophilia 2008; 14: 736-42.